Amsterdam-based Leyden Labs, a platform working to free people from the threat of respiratory viruses has raised $70M (approximately €68M) in funding.

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...

HOPE Therapeuticstm, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") , today ...

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The programs are based on Leyden Labs’ ...